Summary.-Our selection of a potential second-generation platinum compound began with an initial short list of 8 compounds selected on the basis of antitumour and toxicity studies in mice. We now report further, more detailed investigations of the renal toxicity and antitumour activity of one of these compounds, cis-dichloro trans-dihydroxy bis isopropylamine platinum (IV) (CHIP), in comparison with cis-dichloro diammine platinum (II) (Neoplatin). CHIP was a more effective antitumour agent against both alkylating-agent sensitive and resistant strains of the Yoshida sarcoma (YSs and YSR respectively) than was Neoplatin. In addition CHIP produced negligible kidney toxicity as measured by blood urea levels.
berg et al. on the anti-bacterial effects of the soluble salts of platinum (Rosenberg et al., 1965 (Rosenberg et al., , 1967 and, subsequently, on the antitumour properties of cis-dichloro diammine platinum (II) (Neoplatin) (Rosenberg et al., 1969) extensive interest has been generated in the chemical and biological properties of platinum complexes and of other heavy metals. This has culminated in widespread clinical trials of cis-dichloro diammine platinum (II) (cisPt(II), Cisplatin, Neoplatin) mainly against ovarian and testicular tumours (Wiltshaw & Carr, 1974; Higby et al., 1974; Wiltshaw & Kroner, 1976) . Recent clinical and experimental studies using Neoplatin have been reviewed by Rosencweig et al. (1977) and Prestayko et al. (1979) .
Unfortunately, toxic side effects may restrict the clinical utility of Neoplatin.
The toxic effects are mainly nephrotoxicity and nausea and vomiting, but neurotoxicity and myelosuppression have also been reported (Wiltshaw & Carr, 1974; Hill et al., 1974; Kraurs et al., 1979) . Nausea and vomiting have frequently been of sufficient severity to cause the patient to refuse further treatment (Kane et al., 1978 Wittes, 1978) and forced diuresis or manitol hydration are now used routinely (Hayes et al., 1.977; Prestayko et al., 1979) . Cumulative toxicity, however, can still limit the clinical use of Neoplatin (Dentino et al., 1978; Gonzalez-Vitale, 1977) .
Since 1970, some 300 derivatives of cisdichloro diammine platinum (II) have been assessed for antitumour activity by the Institute of Cancer Research (Connors et al., 1972; Braddock et al., 1975) . Many others have been screened at other centres throughout the world (Cleare et al., 1978) . From these data, we selected 8 compounds for further preclinical evaluation (Wilkinson et al., 1978) .
In the present communication we report the antitumour properties and cellular activity of one of the compounds, cisdichloro trans-dihydroxy bis isopropylamine platinum (IV) (CHIP) in comparison with Neoplatin. Measurement of blood urea and urinary protein levels have provided an indication of kidney toxicity. We have compared antitumour activity in a Yoshida sarcoma tumour line sensitive to alkylating agents (YSs), with that achieved using a line exhibiting acquired resistance to alkylating agents (YSR) (Harrap & Furness, 1973) .
Neoplatin has some properties in common with bifunctional alkylating agents, particularly with respect to its ability to bind and cross-link DNA (Roberts & Pascoe, 1972; Zwelling et al., 1978) . The biochemical effects of various platinum complexes on DNA and DNA repair have been recently reviewed by Roberts & Thomson (1979) . We have previously shown that chlorambucil, melphalan and cyclophosphamide, in addition to crosslinking DNA, also induce an increase in nuclear-protein phosphorylation, accompanied by a loss of condensed chromatin in YSs cells (Wilkinson et al., 1979) . These changes have been directly correlated with toxicity, and appear to play a major role in determining cell death following bifunctional alkylating-agent treatment.
We have now investigated the possibility that platinum compounds may also induce similar changes in nuclear-protein phosphorylation and nuclear morphology.
MATERIALS AND METHODS
Both Neoplatin and CHIP were generous gifts from the Johnson Matthey Research Centre (Blount's Court, Sonning Common, Bucks, England). Adenosine 5'-(y-32P)triphosphate was purchased from the Radiochemical Centre (Amersham, Bucks). All other reagents were obtained from Hopkin and Williams Ltd, Chadwell Heath, Essex, or British Drug Houses Ltd, Poole, Dorset. Analytical grades were used whenever available.
Assessment of kidney toxicity.-Blood-urea studies were conducted using groups of 10 normal female Wistar rats. Drugs were administered by i.p. injection in 0-9% NaCl solution. All animals were bled from the tail vein using heparinized Pasteur pipettes, and the blood placed in previously heparinized microfuge tubes containing 10 pul of heparin (1000 i.u./ml). The blood was microfuged for 5 min to produce 200 ,ul of plasma which was stored at 4°C. The plasma was defibrinated and the urea level determined in a Technics Mk 2 auto-analyser as previously described (Marsh et al., 1963) . All rats were weighed daily and the group average calculated.
Urinary protein was assayed daily using Ames Labstix on groups of 3 rats maintained in metabolism cages. Antitumour activity.-Toxicity of both platinum drugs was determined using logarithmically spaced (2-fold) dose levels as previously described (Rosenoer et al., 1966) .
The ability of Neoplatin and CHIP to inhibit the growth of the Yoshida ascites sarcoma in female Wistar rats was determined as previously described (Harrap & Hill, 1969) . Briefly, animals bearing a tumour load of 108 cells which were either sensitive to alkylating-agent toxicity, or had a 50-fold acquired resistance to a wide range of alkylating agents (Harrap & Furness, 1973) were injected s.c. with various doses of either Neoplatin or CHIP dissolved in DMSO. The surviving tumour cells were counted for the subsequent 3 days.
Nuclear-profein phosphorylation. -Nuclei were prepared as previously described (Rickwood et al., 1973) and nuclear-protein phos-6. SHEPHERD (Rickwood et al., 1973) .
Nuclear morphology.-48 h after treatment of tumour-bearing rats, ascites cells were removed from the peritoneal cavity, fixed in gluteraldehyde cacodylate buffer, post-fixed in osmium tetroxide and embedded in Araldite. Ultra-thin sections were stained in an alkaline lead solution before being examined under an electron microscope (Kornovsky, 1961) .
RESULTS
For the toxicological studies described in Figs 1 and 2, both drugs were administered at doses equivalent to 80% of the calculated LD50. Fig. 1 (Fig. 3) . After CHIP treatment the sensitive tumour failed to regrow within 10 days of drug treatment, and was considered to have been "cured". Treatment (Fig. 4) Nuclear-protein phosphorylation Fig. 5 shows the pattern of nuclearprotein phosphorylation in both strains of the Yoshida sarcoma after treatment of tumour-bearing rats with Neoplatin. Nuclear-protein phosphorylation was stimulated in the YSS cells but not in the YSR cells. Fig. 6 shows the pattern of nuclear-protein phosphorylation following CHIP treatment. Increases were seen in both strains, though the extent of phosphorylation was greater in the YSS cells, correlating with their enhanced cell kill.
We also measured nuclear-protein phosphorylation in kidney tissues. Our aim was to determine whether phosphorylation in the kidney could be correlated with nephrotoxicity. As seen in Fig. 7 , Neoplatin stimulated nuclear-protein phos- Neoplatin. Neither Neoplatin nor CHIP induced large increases in the nuclearprotein phosphorylation in liver as seen in the Table. tumour cells after Neoplatin though in sensitive cells the condensed chromatin was lost, with no significant change to the nucleolus. Fig. 9 shows a sensitive cell 48 h after Neoplatin treatment of a tumourbearing rat. The effects are reminiscent of those seen after alkylating agent treatment of Wistar rats bearing the sensitive tumour (Wilkinson et al., 1979) . After treatment of tumour-bearing rats with CHIP, there was a total loss of condensed chromatin in both the sensitive and resistant tumour cells (Fig. 10) . This figure shows a resistant tumour cell 48 h after CHIP treatment of tumour-bearing rats.
There is a total loss of condensed chromatin within the body of the nucleus and around the nuclear membrane.
DISCUSSION
Our data indicate that CHIP has far less host toxicity as measured by body-wt loss, increased blood urea, or urinary protein and chromatin damage, than does Neoplatin, when both are'administered at maximum tolerated levels. The antitumour effects against a spectrum of transplantable rodent tumours indicate that CHIP has an antitumour effect equal to, or greater than, that of Neoplatin (Cleare et al., 1978) . Whilst the clinical efficacy of Neoplatin against a number of human tumours has been demonstrated, its unpleasant side effects necessitate the introduction of a less toxic congener into clinical use. Our current studies would indicate that CHIP is a more selective cis-platinum congener, and is worthy of consideration as an alternative platinum drug. However, more detailed preclinical studies would be required before final evaluation is possible.
Our previous studies on the mode of action of bifunctional alkylating agents have indicated that increased nuclearprotein phosphorylation is an essential prerequisite for DNA damage. Unless nuclear-protein phosphorylation increases, the subsequent cross-linking of DNA does not cause cell death (Wilkinson et al., 1979) . Platinum drugs, in particular Neo-platin, also cross-link DNA (Roberts & Thomson, 1979; Zwelling et al., 1978) and our present studies describe increased nuclear-protein phosphorylation after Neoplatin and CHIP. These changes are equivalent to those seen after bifunctional alkylating agents, and they correlate directly with the selective cell and tissue damage observed.
The chromatin aberrations observed also correlate well with modifications to nuclear morphology in tumour tissues. The condensed nuclear material is lost in tissues exhibiting drug damage. Similar morphological changes have also been found after Neoplatin treatment of Sarcoma 180 (Sodhi, 1977) . These modifications to chromatin material by platinum drugs are reminiscent of those induced by bifunctional alkylating agents (Wilkinson et al., 1979) and indicate further similarities in their molecular modes of action.
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